Alzheimer's Memory Reversed by Natural Molecule - Estaw

In a groundbreaking development that could transform the landscape of Alzheimer’s treatment, scientists have identified a natural molecule capable of reversing memory loss associated with the devastating neurodegenerative disease. Published in the prestigious journal Science Advances, this international research effort has uncovered how oxidized nicotinamide adenine dinucleotide (NAD⁺) works at the cellular level to restore cognitive function in Alzheimer’s disease models.

The Molecular Breakthrough

The study, led by Associate Professor Evandro Fei Fang from the University of Oslo and Akershus University Hospital, reveals a previously unknown mechanism by which NAD⁺ protects the brain from Alzheimer’s progression. The researchers discovered that this natural metabolite corrects RNA splicing errors—a fundamental cellular process that goes awry in Alzheimer’s patients.

“In Alzheimer’s disease, RNA splicing—which tells cells how to assemble proteins—goes awry, producing dysfunctional proteins that accelerate the irreversible death of neurons,” explains the research team. The discovery shows that NAD⁺ works through a specific protein called EVA1C to restore proper gene function and improve memory performance.

Understanding RNA Splicing

For those unfamiliar with cellular biology, RNA splicing is like a cellular editing process. Genes are first transcribed into RNA, but this initial RNA contains non-coding sequences called introns that must be removed, and coding sequences called exons that must be joined together. This editing process allows a single gene to produce multiple protein variants, depending on which exons are included or excluded.

In Alzheimer’s disease, this splicing process becomes faulty, leading to the production of harmful proteins that accumulate in the brain. The new research shows that NAD⁺ helps correct these splicing errors through the EVA1C protein pathway.

International Collaboration Yields Results

This significant discovery emerged from an international collaboration involving researchers from the University of Oslo and Akershus University Hospital in Norway, Jinan University in China, and the University of Minho in Portugal. Such global cooperation reflects the magnitude of the Alzheimer’s challenge and the need for coordinated scientific efforts.

The research team validated their findings across multiple models: worms, mice, and human brain samples. In human brain tissue from Alzheimer’s patients, they found that EVA1C protein levels were significantly reduced in the hippocampus and entorhinal cortex—two brain regions critically linked to memory formation and early disease progression.

The Critical Role of EVA1C

The EVA1C protein proved to be essential for NAD⁺’s neuroprotective effects. When researchers deliberately reduced EVA1C levels in laboratory models, the beneficial effects of NAD⁺ disappeared entirely. This confirmed that the EVA1C pathway is not just associated with the protective mechanism—it’s absolutely required for it to function.

“Notably, we found when the EVA1C gene was knocked down, these benefits were lost, confirming that EVA1C is essential for NAD⁺-mediated neuroprotection,” said Evandro Fei Fang-Stavem, an associate professor at UiO.

The study reveals that NAD⁺ promotes a specific form of EVA1C that efficiently binds to essential proteins involved in protein folding and clearance. This creates a molecular connection between three processes that are critically impaired in Alzheimer’s disease: metabolic homeostasis, RNA splicing, and protein management.

Context: The Desperate Need for Better Treatments

The significance of this discovery becomes clear when considering the limited success of current Alzheimer’s treatments. According to research published in Alzheimer’s Research and Therapy, the failure rate for Alzheimer’s disease drug development is a staggering 99.6%. Over the past 15 years, more than 400 clinical trials of therapeutics for Alzheimer disease have been registered, with a failure rate of nearly 100%.

Current treatments primarily focus on two approaches: cholinesterase inhibitors that boost levels of acetylcholine (a neurotransmitter important for memory) and newer drugs targeting amyloid plaques. However, these treatments offer only modest benefits to patients.

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide temporary symptom relief but don’t alter disease progression
Amyloid-targeting drugs like lecanemab and donanemab can slow cognitive decline by about 27% over 18 months but come with serious side effects
No treatment currently available can restore lost memory function or halt neurodegeneration

With nearly 40 million people worldwide living with Alzheimer’s disease, and numbers expected to triple by 2050, the need for fundamentally different approaches has never been more urgent.

Therapeutic Potential and Future Directions

The research has profound implications for Alzheimer’s treatment development. NAD⁺ is already being studied in multiple clinical trials for various conditions, and its safety profile is relatively well-established. Nicotinamide riboside, a precursor to NAD⁺ that’s easily absorbed after oral administration, is already available as a supplement.

“Als die Wissenschaftler in Tiermodellen … zu korrigieren. ‘Wir konnten zeigen, dass NAD⁺ auf molekularer Ebene Fehler ausgleicht, die bei Alzheimer gehäuft auftreten’”, sagt Studienleiter Fang. (Translation: “When the scientists in animal models … to correct. ‘We were able to show that NAD⁺ corrects errors at the molecular level that occur frequently in Alzheimer’s’”)

“This connection links metabolic homeostasis, RNA splicing processes and protein management, three processes that are critically impaired in AD,” noted the research team. By establishing the connection between NAD⁺ and EVA1C, this study lays the groundwork for new therapeutic strategies.

What Makes This Different?

Unlike existing treatments that target symptoms or single pathological features like amyloid plaques, this approach addresses a fundamental cellular mechanism that underlies neurodegeneration. By correcting RNA splicing errors, NAD⁺ potentially addresses the root cause of multiple downstream problems simultaneously.

The researchers suggest that maintaining NAD⁺ levels could help preserve neuronal identity and delay cognitive decline, potentially leading to combination treatments that enhance RNA splicing. This could represent a paradigm shift from merely managing symptoms to actually repairing cellular damage.

Looking Forward

While these results are promising, it’s important to note that clinical applications in humans may still be years away. The researchers emphasize that further studies are needed to establish optimal dosing, delivery methods, and safety profiles for Alzheimer’s patients specifically.

Nevertheless, this discovery represents one of the most promising developments in Alzheimer’s research in recent years. By targeting a basic cellular mechanism rather than just symptoms, it offers hope for treatments that could genuinely restore lost cognitive function rather than simply slowing decline.

As Evandro Fang noted about his previous work on NAD⁺ and Alzheimer’s: “This has high clinical relevance, in the short and long term.” With clinical trials of NAD⁺ precursors already underway for Alzheimer’s patients, the path from laboratory discovery to potential patient treatment may be shorter than for many other experimental approaches.

For the millions of families affected by Alzheimer’s worldwide, this research provides a much-needed beacon of hope in the fight against one of humanity’s most challenging diseases.

Alzheimer’s Memory Reversed by Natural Molecule